Biotech AssistantIndependent biopharma research
RESEARCH / LITERATURE

Research Literature

Find research, methods, and reviews across our scientific fields.

One collection · Original publication dates · Authors, journals & DOIs

mRNA / LNP 67

Duplicate DOIs are merged. This is a selected collection, not an exhaustive bibliography.

Clear filtersExport results · RIS ↓
Original research
ACS Applied Materials & Interfaces

Stabilizing Anionic mRNA Lipid Nanoparticles by Cleavable Crosslinking of Cholesterol

Yunhe Su; Joseph Choy; Xiang Liu; Yining Zhu; Jinghan Lin; Christine Wei; Kailei D. Goodier; Di Yu; Leonardo Cheng; Milan Patel; Xiaoya Lu; Jingyao Ma; Jialiang Wang; Hai-Quan Mao

Acid-cleavable cholesterol-derived crosslinkers and PEG-diamines stabilized anionic LNPs that otherwise lost activity during purification. By tuning crosslinking architecture, researchers balanced structural integrity with RNA release and improved splenic mRNA expression. Mechanistic analyses implicated intracellular processing as well as release behavior. These formulation-specific animal results do not establish general T-cell targeting or clinical manufacturing readiness.

mRNA / LNP
Read guide →Original paper ↗

DOI: 10.1021/acsami.6c06888

Methods
ACS Nano

Nanopore-Mediated Assembly Enables Precise and Continuous Synthesis of mRNA-Encapsulated Lipid Nanoparticles for COVID-19 Vaccines

Zhixiang Liu; William Stewart; Yilong Teng; Yufeng Song; Maoping Tang; Yuxuan Guo; Xue-Qing Zhang; Kamalesh K. Sirkar; Xiaoyang Xu

A hollow-fiber membrane platform uses dense nanopore arrays to control localized mixing during lipid nanoparticle assembly. The continuous process generated tunable particle sizes, narrow distributions, and high encapsulation, with particle properties linked to membrane pore size. Multiple lipid chemistries and nucleic acid payloads were compatible, and cell and animal studies supported activity. Commercial GMP performance remains to be established.

mRNA / LNP
Read guide →Original paper ↗

DOI: 10.1021/acsnano.6c00729

Original research
Advanced Science

Optimized Lipid Nanoparticles with Tail‐Modified Ionizable Lipids for Safer mRNA Delivery

Seo‐Hyeon Bae; Jisun Lee; Jae‐Hun Ahn; Hosam Choi; Huijeong Choi; Jungmin Kim; Minho Kang; Ho Rim Oh; So Hyun Park; Eun Young Oh; Sanghyuk Jeon; Yeeun Lee; Yu‐Sun Lee; Na‐Young Lee; Hee‐Jin Bae; Jina Kwak; Jooil Kim; Nakyung Lee; Beomsun Kang; Ji‐Hye Kim; Eunsaem Song; Daesub Song; Hyunho Yoon; Sang‐Myeong Lee; Hyewon Youn; Kiyoun Lee; Byeong‐Cheol Kang; Jae‐Hwan Nam

A library of 56 ionizable lipids combined biodegradable disulfide linkages with different hydrophobic tail lengths and branching patterns. Structure-activity testing linked tail architecture to endosomal escape, translation, and biocompatibility. Optimized particles reduced cytotoxicity and cytokine induction, with immune-response evaluation extending to a nonhuman primate model. These findings support lipid design, rather than establishing human safety.

mRNA / LNP
Read guide →Original paper ↗

DOI: 10.1002/advs.76539

Original research
Angewandte Chemie International Edition

Ligand‐Mediated Reprogramming Redirects Liver‐Tropic Ionizable Lipid Nanoparticles for Lung‐Selective mRNA Delivery

Zhuxiao Gu; Xinhong Xiong; Xiang Chen; Hanwen Zhang; Ning Gu; Lulu Xue

Starting with a liver-tropic lead from 90 degradable lipidoids, researchers attached small-molecule ligands to redirect delivery toward the lung. The modified particles showed increased vitronectin association and enhanced pulmonary mRNA expression, with genome-editing proof of concept. This modular chemical approach retains the parent scaffold, but its targeting performance remains demonstrated in preclinical experimental conditions.

mRNA / LNP
Read guide →Original paper ↗

DOI: 10.1002/anie.6080664

Original research
Nature Communications

Pulmonary mRNA-LNP vaccines for rapid and durable protection against bacterial infection

Anqi Wei; Yu Miao; Zhou Yuan; Guanghui Li; Dexuan Lei; Yinyu Ma; Zhiwei Guo; Yuansong Sun; Tianhao Ding; Kaisong Tian; Qin He; Zui Zhang; Lianfeng Fan; Changyou Zhan; Xiaoli Wei

Researchers designed a pulmonary mRNA-LNP vaccine that combines early innate immune activation with later antigen-specific protection. Intratracheal vaccination primed neutrophils and macrophages and subsequently generated adaptive responses against Pseudomonas aeruginosa, including drug-resistant isolates. Single-cell profiling supported a coordinated immune mechanism. The protection experiments were conducted in female mice, rather than patients.

mRNA / LNP
Read guide →Original paper ↗

DOI: 10.1038/s41467-026-75413-x

Original research
Communications Biology

Biologically engineered vectors enable topical mRNA delivery for skin regeneration

Julie Gérard; Héloïse Pilet; Charbel Bouez; Xun Du; Yong Chen; Yogeshvar N. Kalia; Pascal Clayette; Bruno A. Bernard; Nicolas Grandchamp

This study developed biologically assembled RNA delivery particles, termed RNA-BEVs, for topical skin applications. The vectors transferred functional mRNA into keratinocytes and reconstructed epidermis, enabling transient protein production. In diabetic rats, wound repair histology improved relative to the tested mRNA-LNP comparator. These biologically engineered vectors are a distinct carrier class, rather than conventional lipid nanoparticles.

mRNA / LNP
Read guide →Original paper ↗

DOI: 10.1038/s42003-026-10651-9

Original research
Proceedings of the National Academy of Sciences

mRNA lipid nanoparticle cancer vaccine platform delivering multiple STING activators for enhanced antitumor activity

Ye Zeng; Junchao Xu; Jinjin Wang; Lulu Xue; Jiageng Liu; Hannah C. Geisler; Xu Ma; Jilian R. Melamed; Qiangqiang Shi; Marshall S. Padilla; Zhangyi Luo; Jingcheng Zhu; Ajay S. Thatte; Christian G. Figueroa-Espada; Melgious Jin Yan Ang; Amanda M. Murray; Hannah M. Yamagata; Dongyoon Kim; Ann E. Metzloff; Drew Weissman; Michael J. Mitchell

An ionizable-lipid screening campaign produced an LNP formulation for dendritic-cell mRNA delivery. Researchers coencapsulated tumor-antigen mRNA, cyclic di-AMP, and manganese to coordinate antigen production with STING activation. The combination enhanced antigen presentation, tumor-specific T-cell responses, and antitumor activity in experimental models. It is a preclinical platform, with no demonstrated patient benefit in this report.

mRNA / LNP
Read guide →Original paper ↗

DOI: 10.1073/pnas.2525718123

AI assistant ↗